Kai Li

Dr. Kai Li


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
RJRicheng Jiang
Richeng Jiang
ZJZiliang Jin
Ziliang Jin
ZLZhujun Liu
Zhujun Liu
LSLeina Sun
Leina Sun
LWLiuchun Wang
Liuchun Wang
KLKai Li
Kai Li

20 February 2014 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
XWXinyue Wang
Xinyue Wang
RJRicheng Jiang
Richeng Jiang
KLKai Li
Kai Li

25 March 2020 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
TQTingting Qin
Tingting Qin
ZLZhujun Liu
Zhujun Liu
JWJing Wang
Jing Wang
JXJunling Xia
Junling Xia
SLShaochuan Liu
Shaochuan Liu
KLKai Li
Kai Li
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

24 July 2017 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YWYu-Qian Wang
Yu-Qian Wang
QZQiong-Jie Zhi
Qiong-Jie Zhi
XWXin-Yue Wang
Xin-Yue Wang
DYDong-Sheng Yue
Dong-Sheng Yue
KLKai Li
Kai Li
RJRicheng Jiang
Richeng Jiang
The aim of the present study was to investigate the prognostic value of the combined platelet (PLT), fibrinogen (FBG), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) (CO‑NPF) for postoperative outcomes in patients with lung adenosquamous cancer (ASC). Test results from patients who presented at The Cancer Institute and Hospital of Tianjin Medical University between January 2005 and December 2013 were retrospectively reviewed. CO‑NPF was scored between 0 and 4 according to increased PLT, FBG, NLR and PLR prior to being split into two groups based on the presence (≥2) or absence (<2) of the combination of increased inflammatory indexes. In total, data from 134 patients with ASC were reviewed for the present study. Multivariate analysis identified that increased CO‑NPF (P=0.001 and P<0.001, respectively), PLR (P=0.011 and P=0.001, respectively) and FBG (P=0.001 and P<0.001, respectively) were independently associated with shorter disease‑free survival (DFS) and overall survival (OS). NLR (P=0.006) and PLT (P=0.001) were independent prognostic factors for OS. The area under the receiver operating characteristic curves of CO‑NPF (area under the curve, 0.652, P=0.008, 95% confidence interval, 0.551‑0.752) was increased compared with NLR, PLR, PLT and FBG individually, suggesting that CO‑NPF has greater predictive value. CO‑NPF was significantly and independently associated with shorter DFS and OS, and had greater predictive value compared with NLR, PLR, PLT and FBG in patients with ASC who underwent surgery.

19 August 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
JLJun Lu
Jun Lu
HZHua Zhong
Hua Zhong
JWJun Wu
Jun Wu
TCTianqing Chu
Tianqing Chu
LZLele Zhang
Lele Zhang
BHBaohui Han
Baohui Han
Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy through anlotinib therapy) study participants. The results indicate that patients receiving no benefit can be mainly excluded via analysis of ARID1A and BRCA2 genetic profiling. For patients with no durable benefit and durable clinical benefit patients, three predictors: germline and somatic mutation burden (G+S MB), nonsynonymous and synonymous mutation burden (N+S MB), and unfavorable mutation score of circulating DNA profiling are identified. Through integrating the advantages and disadvantages of three independent predictors, the tumor mutation index (TMI) is established as a prediction model and the patients who are very likely to benefit more from anlotinib therapy are identified. Furthermore, the IDH1exon 4 mutation is identified as an unfavorable factor for anlotinib therapy under TMI‐based stratification, and the TMI plus IDH1exon 4 mutation status potentially predicts response to anlotinib. Collectively, this study provides a circulating DNA sequencing–based stratification method for identifying anlotinib responders via a noninvasive approach, and thus potentially improves the clinical outcome of NSCLC patients receiving third‐line therapy.

27 August 2018 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CZCuicui Zhang
Cuicui Zhang
YJYongsheng Jia
Yongsheng Jia
YJYanan Jia
Yanan Jia
XZXiaoling Zhang
Xiaoling Zhang
KLKai Li
Kai Li